Welcome to our dedicated page for Nutex Health SEC filings (Ticker: NUTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nutex Health Inc. (NUTX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nutex Health is a Houston-based, physician-led healthcare management and operations company with a Hospital Division and a Population Health Management Division, and its filings explain how these segments are reflected in its financial statements and risk disclosures.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Nutex Health presents consolidated financial statements, segment revenue for its hospital and population health management divisions, details on operating costs, noncontrolling interests and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Recent filings also describe restatements of prior financial statements, including reclassification of non-cash stock-based compensation obligations related to under-construction and ramping hospitals, and explain that these adjustments were non-cash and did not materially affect key metrics such as revenue, liquidity, operating cash flow, Adjusted EBITDA or patient visits for the periods presented.
Current reports on Form 8-K document material events such as the release of quarterly and annual earnings, notices from Nasdaq regarding timely filing requirements and subsequent confirmation of regained compliance, appointment of senior executives, authorization of stock repurchase programs and disclosure of litigation, including a derivative action filed in federal court. These 8-K filings help investors understand significant developments between periodic reports.
On Stock Titan, Nutex Health filings are updated in near real time from EDGAR and are accompanied by AI-powered summaries that highlight key points from lengthy documents. Users can quickly see where Nutex Health discusses topics such as arbitration-related revenue through the Independent Dispute Resolution (IDR) process, capital structure, stock-based compensation, and legal or regulatory matters. The filings page also surfaces ownership and transaction data from forms such as Form 4, enabling readers to review insider transactions alongside the company’s broader financial and operational disclosures.
Nutex Health Inc. reported higher profitability for the three months ended March 31, 2026. Total revenue rose 2.2% to $216.5 million, led by hospital division revenue of $207.6 million and modest growth in population health management. Hospital division visits increased 3.1% year over year to 49,742.
Net income attributable to Nutex Health climbed to $46.8 million, with diluted EPS of $6.52, up from $3.33 a year earlier. EBITDA was $68.3 million, while Adjusted EBITDA declined to $57.6 million from $72.8 million. Operating cash flow improved to $75.5 million, cash and cash equivalents reached $207.3 million, and long-term debt, net decreased to $24.3 million.
Nutex Health Inc. reported strong Q1 2026 results with higher profit and cash generation while continuing heavy use of arbitration under the No Surprises Act.
Total revenue was $216.5 million, up modestly from $211.8 million a year earlier, driven mainly by the hospital division’s $207.6 million. Net income rose to $62.8 million, with $46.8 million attributable to Nutex, more than double the prior-year $21.2 million. Basic earnings per share increased to $6.70, and operating income was $81.3 million.
Operating cash flow reached $75.5 million, lifting cash, cash equivalents and restricted cash to $210.6 million at March 31, 2026. The company spent $31.7 million on stock repurchases and retired 200,444 shares, while also settling certain disputes with former doctor owners and retiring additional shares.
Nutex’s business remains highly exposed to out-of-network reimbursement and arbitration. Arbitration-related costs for hospital and professional services were $46.1 million in the quarter, and accrued arbitration expenses increased to $56.8 million, reflecting the scale and complexity of the Independent Dispute Resolution process.
Nutex Health Inc. Schedule 13G filing shows BlackRock, Inc. reported beneficial ownership of 367,633 shares of Common Stock, representing 5.3% of the class as of 03/31/2026. The filing states BlackRock has sole voting power over 361,034 shares and sole dispositive power over 367,633 shares. The cover notes that these holdings reflect certain Reporting Business Units of BlackRock and do not include securities held by other BlackRock business units. The document is signed by a BlackRock Managing Director on 04/27/2026.
Reed Michael Lee reported acquisition or exercise transactions in this Form 4 filing.
Nutex Health Inc. director Michael Lee received a grant of 823 Restricted Stock Units (RSUs) as equity compensation. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest 100% on April 23, 2027, with pro-rata vesting if he leaves the company without cause during the vesting period. Following this award, Lee holds a total of 1,426 RSUs directly. This filing reflects a compensation-related stock unit grant, not an open-market share purchase or sale.
Saunders Scott J reported acquisition or exercise transactions in this Form 4 filing.
Nutex Health Inc. director Scott J. Saunders received a grant of 823 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Nutex common stock upon vesting. These RSUs vest 100% on April 23, 2027, and will vest on a pro-rata basis if he leaves the company without cause before that date. Following this award, Saunders holds a total of 1,426 RSUs directly.
Nutex Health Inc. director Frank E. Jaumot received a grant of 823 Restricted Stock Units (RSUs) on April 23, 2026 as equity compensation. Each RSU represents a contingent right to receive one share of common stock upon vesting. These RSUs vest 100% on April 23, 2027, with pro‑rata vesting if he leaves the company without cause during the vesting period. Following this award, Jaumot holds 1,426 RSUs directly. This is a compensation-related acquisition, not an open‑market stock purchase or sale.
Grenas Cheryl Yvonne reported acquisition or exercise transactions in this Form 4 filing.
Nutex Health Inc. director Cheryl Yvonne Grenas received a grant of 823 Restricted Stock Units (RSUs), each representing one share of common stock upon vesting. The RSUs vest 100% on April 23, 2027, with pro-rata vesting if she leaves the company without cause before that date. Following this award, she holds 1,426 RSUs directly.
Nutex Health Inc. held its annual stockholder meeting on April 23, 2026. There were 5,628,591 common shares eligible to vote, and 3,900,175 shares were voted, representing about 69.29% of eligible shares.
All seven director nominees were elected to serve until the 2027 annual meeting. Stockholders also approved, on an advisory basis, the compensation of the named executive officers. In addition, stockholders ratified Grant Thornton LLP as Nutex Health’s independent registered public accounting firm for the year ending December 31, 2026.
Nutex Health Inc. director and CEO Thomas T. Vo reported two insider equity transactions. First, an entity he owns and controls, Micro Hospital Holdings LLC, received 184,071 shares of common stock in a private issuance. These shares relate to Vo’s pro-rata interest in two under-construction hospitals previously transferred to Nutex Health Holdco LLC under an Agreement and Plan of Merger. Following this issuance, Micro Hospital Holdings LLC holds 2,027,267 common shares indirectly for Vo.
Separately, Vo exercised 4,841 restricted stock units (RSUs) into an equal number of common shares at a stated price of $0.00 per share, with 16,507 RSUs shown as beneficially owned afterward. The Form 4 also corrects the previously reported RSU balance from an earlier filing.
Nutex Health Inc. reported that Chief Operating Officer Wesley Shane Bamburg acquired 2,411 restricted stock units (RSUs) on March 11, 2026 as equity compensation. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029, aligning Bamburg’s incentives with the company’s long-term performance rather than reflecting any open-market share purchase or sale.